Empowering Tomorrow: TASQC’s impact on young hearts – Viral Load Suppression efforts for a young girl in Mwenezi District
Ruvarashe*, a 14-year-old girl from Mwenezi, was diagnosed of HIV positive in September 2011 when she was 2 years old. Beginning her antiretroviral treatment in June 2012, her journey was marked by struggles and challenges. Over the years, her viral load fluctuated, with moments of uncertainty and fear.
The revelation of her HIV status led to ridicule and ostracization by her peers, causing her to stop taking her vital medications. Amidst her medical battle, Ruvarashe’s mental health suffered. She withdrew from the world, was unkempt and disinterested, burdened by the weight of stigma and isolation at school. Her viral load, taken in January 2024 was high at 329 818copies/ml. The viral load prior to this one was suppressed.
The TASQC team intervened, providing crucial education and support. Through enhanced adherence counselling (EAC) sessions, Ruvarashe learned to confront stigma with resilience and understanding. Her mother was encouraged to actively support her, and the school community was sensitized to the importance of acceptance and compassion. With each session, her outlook brightened, and she began to engage with life once more, attending her adolescent clinics with a newfound sense of joy and connection.
Through dedicated efforts and unwavering support of the TASQC Programme, her mother, guided on the significance of family involvement, stood by her daughter with unwavering love and understanding. Empowered with strategies to combat stigma, Ruvarashe faced her challenges with newfound strength and resilience. School teachers, informed of her situation, initiated educational sessions on HIV/AIDS, fostering a culture of acceptance and empathy among students. By the conclusion of the third EAC session, a profound shift had occurred in her attitude towards herself and others. Residing with her mother and two HIV-negative brothers, she navigates life’s challenges with resilience and courage. In April 2024 her viral load was now 129cc/ml. Her current ART regimen is Dolutegravir/ Tenofovir/Lamivudine (TLD) from June 2020 to date.
While her journey has seen remarkable progress, Ruvarashe’s continued need for support and counselling remains paramount. With ongoing guidance and care, she is empowered to face the future with hope and determination.
*Not her real name